Johannes Gutenberg-Universität Mainz
- 6131/39-0
Doehner, Hartmut; Weber, Daniela; Krzykalla, Julia et al.
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with <i>NPM1</i>-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trialLANCET HAEMATOLOGY. Bd. 10. H. 7. 2023
Uhe, Tobias; Wasser, Katrin; Weber-Krueger, Mark et al.
Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism-the Find-AF 2 study-rationale and designAMERICAN HEART JOURNAL. Bd. 265. 2023 S. 66-76
Lieb, Klaus; Brückner, Annette; Geschke, Katharina et al.
Intensivkurs Psychiatrie und Psychotherapie10. Aufl. München: Urban & Fischer 2023 578 S.
Van Der Perk, M. E. Madeleine; Broer, Linda; Yasui, Yutaka et al.
INTER-INDIVIDUAL VARIATION IN GONADOTOXICITY IN FEMALE CHILDHOOD CANCER SURVIVORS - A GENOME-WIDE ASSOCIATION STUDY: RESULTS FROM THE PANCARELIFE STUDYPEDIATRIC BLOOD & CANCER. Bd. 70. 2023 S. S130-S131
Hartig, Renee; Karimi, Ali; Evrard, Henry C.
Interconnected sub-networks of the macaque monkey gustatory connectomeFRONTIERS IN NEUROSCIENCE. Bd. 16. 2023
Jorg, Tobias; Mildenberger, Peter; Stoehr, Fabian
Interdisciplinary case discussionsRADIOLOGIE. 2023
Reith, W.; Mildenberger, P.; Herold, C. et al.
Interdisciplinary Discussions, Consultative Findings and Communication of ResultsRADIOLOGIE. Bd. 63. H. 2. 2023 S. 87-88
Lahmer, T.; Stock, K.; Rasch, S. et al.
Interdisciplinary ultrasound-guided, minimally invasive autopsy in COVID-19-deceased patients in the intensive care unit of a university hospital. A proof-of-concept studyPATHOLOGIE. Bd. 44. H. 3. 2023 S. 193-197
Klemperer, David; Lieb, Klaus
Interessenkonflikte und LeitlinienC. Günster,J. Klauber, D. Klemperer, M. Nothacker, B.-P. Robra, C. Schmucker (Hrsg). Versorgungs-Report Leitlinien - Evidenz für die Praxis. Medizinisch Wissenschaftliche Verlagsgesellschaft 2023
Bartsch, Rupert; Harbeck, Nadia; Wrobel, Denise et al.
Interim analysis (n=200) from ELEANOR: a multinational, prospective, non-interventional study among patients with HER2+and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routineCANCER RESEARCH. Bd. 83. H. 5. 2023